Insider Selling: BeiGene, Ltd. (NASDAQ:BGNE) COO Sells $100,000.00 in Stock

BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu sold 500 shares of the firm’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $200.00, for a total value of $100,000.00. Following the completion of the transaction, the chief operating officer now owns 4,500 shares in the company, valued at $900,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Xiaobin Wu also recently made the following trade(s):

• On Thursday, September 19th, Xiaobin Wu sold 4,500 shares of BeiGene stock. The stock was sold at an average price of $200.14, for a total value of $900,630.00.
• On Tuesday, September 3rd, Xiaobin Wu sold 5,556 shares of BeiGene stock. The stock was sold at an average price of $189.65, for a total value of $1,053,695.40.
• On Monday, June 24th, Xiaobin Wu sold 1,459 shares of BeiGene stock. The stock was sold at an average price of $159.79, for a total value of $233,133.61.

BeiGene Trading Up 1.7 %

BeiGene stock opened at $201.99 on Friday. The company has a market cap of $19.57 billion, a price-to-earnings ratio of -26.68 and a beta of 0.61. The firm has a 50-day moving average of $182.24 and a 200-day moving average of $164.48. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75. BeiGene, Ltd. has a one year low of $126.97 and a one year high of $215.00.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($1.15) EPS for the quarter, beating the consensus estimate of ($2.27) by $1.12. The firm had revenue of $929.20 million during the quarter, compared to analysts’ expectations of $810.34 million. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The business’s quarterly revenue was up 56.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($3.64) earnings per share. On average, equities analysts expect that BeiGene, Ltd. will post -5.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BGNE has been the topic of several research analyst reports. Citigroup raised their target price on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Bank of America dropped their price objective on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a report on Tuesday, July 9th. JMP Securities assumed coverage on shares of BeiGene in a research note on Wednesday. They issued a “market outperform” rating and a $288.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $241.21.

Hedge Funds Weigh In On BeiGene

A number of institutional investors have recently added to or reduced their stakes in BGNE. Capital International Investors lifted its stake in BeiGene by 11.5% in the first quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock valued at $1,104,806,000 after acquiring an additional 727,556 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in BeiGene by 6.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after purchasing an additional 117,905 shares during the last quarter. Capital International Inc. CA grew its holdings in BeiGene by 6.0% during the first quarter. Capital International Inc. CA now owns 858,364 shares of the company’s stock worth $134,240,000 after purchasing an additional 48,615 shares during the period. Point72 Asset Management L.P. acquired a new position in BeiGene during the second quarter worth approximately $54,412,000. Finally, First Trust Advisors LP acquired a new position in BeiGene during the fourth quarter worth approximately $39,632,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.